Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9CDPO)

• Drug Name: TBC-M4 Drug Info
• Synonyms: MVA-based HIV subtype C vaccine, IAVI; Modified vaccinia Ankara-based HIV subtype C vaccine, International AIDS Vaccine Initiative

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM9CDPO

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[3]
MGD014	DMZN5QX	Human immunodeficiency virus-1 infection	1C62	Phase 1	[4]
PENNVAX-6	DM0BNLC	Human immunodeficiency virus infection	1C62	Phase 1	[5]
Ad5-ENVA-48	DMMBQV3	Human immunodeficiency virus-1 infection	1C62	Phase 1	[6]
GPG	DMYR7LO	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1/2	[7]

Drug(s) Targeting Human immunodeficiency virus GAG protein (HIV gag)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bevirimat	DML2D8Q	Human immunodeficiency virus infection	1C62	Phase 2	[8]
LIPO-5	DMWY0V1	Human immunodeficiency virus infection	1C62	Phase 2	[9]
Ad35-GRIN	DM4L28K	Human immunodeficiency virus infection	1C62	Phase 1/2	[3]
Ad35-GRIN/ENV	DMG82ZA	Human immunodeficiency virus infection	1C62	Phase 1	[3]
RVSVIN HIV-1 gag vaccine	DMYRPC8	Human immunodeficiency virus infection	1C62	Phase 1	[10]
GSK-732461	DMJ0ZB6	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[11]
PA-1050040	DMF4KPM	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[12]
Gem 92	DM4ZDVY	Human immunodeficiency virus-1 infection	1C62	Discontinued in Phase 1	[13]
MPC-9055	DMCMNKV	Human immunodeficiency virus infection	1C62	Discontinued in Phase 1	[14]
MPI-461359	DMAVD4Q	Human immunodeficiency virus infection	1C62	Terminated	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)	TTEC2T3	ENV_HV1H2	Not Available	[2]
Human immunodeficiency virus GAG protein (HIV gag)	TTFGZB6	GAG_HV1H2	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00902824) Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine. U.S. National Institutes of Health.
• [2] A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
• [3] A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
• [4] Clinical pipeline report, company report or official report of MacroGenics.
• [5] Company report (Inovio)
• [6] ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
• [7] GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20.
• [8] Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
• [9] HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
• [10] Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81.
• [11] Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013.
• [12] US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections.
• [13] Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3.
• [14] New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087.
• [15] Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63.